Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.…
Microbial Fermentation Technology - Global Strategic Business Report: Secure Share of the $45.2B Market by 2030 as Lonza, Roche, Novozymes and Biocon Accelerate Scale
Novozymes (CPH: NSIS-B) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Specialty Chemicals industry, part of the Basic Materials sector, and reports about 10,933 employees.
The shares were at 441.40 DKK on 20 November 2026, up 7.2% over 52 weeks. Its 52-week range is 336.80 DKK to 484.70 DKK: the price is 8.9% below the high and 31.1% above the low.
At a market capitalisation of 205.74B DKK, it trades at 40.4 times trailing earnings and 25.4 times forward earnings. The median trailing P/E of its 18 largest Specialty Chemicals peers is 32.3, a premium of 25% for NSIS-B. It pays a dividend yielding 1.50% (it pays out 61% of its earnings), against a median of 1.98% among the dividend payers in that peer group.
Novozymes reports return on equity of 5.4%, an operating margin of 23.4% and revenue up 7.1% year over year.
Its debt exceeds its cash by 2.68B EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 15 analysts cover the stock, with an average rating of Buy; their mean price target of 513.67 DKK is 16.4% above the current price. The next earnings report is expected on 24 February 2027.